Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari. Cardiovasc Diabetol 2019
Times Cited: 19
Times Cited: 19
Times Cited
Times Co-cited
Similarity
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N. Engl. J. Med. 2015
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N. Engl. J. Med. 2015
63
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N. Engl. J. Med. 2019
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N. Engl. J. Med. 2019
57
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N. Engl. J. Med. 2017
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N. Engl. J. Med. 2017
57
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N. Engl. J. Med. 2019
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N. Engl. J. Med. 2019
47
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
42
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N. Engl. J. Med. 2019
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N. Engl. J. Med. 2019
42
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N. Engl. J. Med. 2016
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N. Engl. J. Med. 2016
36
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Eri T Kato, Michael G Silverman, Ofri Mosenzon, Thomas A Zelniker, Avivit Cahn, Remo H M Furtado, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
Eri T Kato, Michael G Silverman, Ofri Mosenzon, Thomas A Zelniker, Avivit Cahn, Remo H M Furtado, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter,[...]. Circulation 2019
31
Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart.
Ivana Vrhovac, Daniela Balen Eror, Dirk Klessen, Christa Burger, Davorka Breljak, Ognjen Kraus, Nikola Radović, Stipe Jadrijević, Ivan Aleksic, Thorsten Walles,[...]. Pflugers Arch. 2015
Ivana Vrhovac, Daniela Balen Eror, Dirk Klessen, Christa Burger, Davorka Breljak, Ognjen Kraus, Nikola Radović, Stipe Jadrijević, Ivan Aleksic, Thorsten Walles,[...]. Pflugers Arch. 2015
26
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
26
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.
Subodh Verma, John J V McMurray. Diabetologia 2018
Subodh Verma, John J V McMurray. Diabetologia 2018
26
Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2.
Chiara Ghezzi, Donald D F Loo, Ernest M Wright. Diabetologia 2018
Chiara Ghezzi, Donald D F Loo, Ernest M Wright. Diabetologia 2018
21
Expression cloning and cDNA sequencing of the Na+/glucose co-transporter.
M A Hediger, M J Coady, T S Ikeda, E M Wright. Nature 1987
M A Hediger, M J Coady, T S Ikeda, E M Wright. Nature 1987
21
The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes.
Yan-Ling He, William Haynes, Charles D Meyers, Ahmed Amer, Yiming Zhang, Ping Mahling, Anisha E Mendonza, Shenglin Ma, William Chutkow, Eric Bachman. Diabetes Obes Metab 2019
Yan-Ling He, William Haynes, Charles D Meyers, Ahmed Amer, Yiming Zhang, Ping Mahling, Anisha E Mendonza, Shenglin Ma, William Chutkow, Eric Bachman. Diabetes Obes Metab 2019
21
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N. Engl. J. Med. 2017
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N. Engl. J. Med. 2017
21
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
21
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat. Med. 2015
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat. Med. 2015
21
Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
Toshiyuki Hayashi, Tomoyasu Fukui, Noriko Nakanishi, Saki Yamamoto, Masako Tomoyasu, Anna Osamura, Makoto Ohara, Takeshi Yamamoto, Yasuki Ito, Tsutomu Hirano. Cardiovasc Diabetol 2017
Toshiyuki Hayashi, Tomoyasu Fukui, Noriko Nakanishi, Saki Yamamoto, Masako Tomoyasu, Anna Osamura, Makoto Ohara, Takeshi Yamamoto, Yasuki Ito, Tsutomu Hirano. Cardiovasc Diabetol 2017
21
SGLT2 mediates glucose reabsorption in the early proximal tubule.
Volker Vallon, Kenneth A Platt, Robyn Cunard, Jana Schroth, Jean Whaley, Scott C Thomson, Hermann Koepsell, Timo Rieg. J. Am. Soc. Nephrol. 2011
Volker Vallon, Kenneth A Platt, Robyn Cunard, Jana Schroth, Jean Whaley, Scott C Thomson, Hermann Koepsell, Timo Rieg. J. Am. Soc. Nephrol. 2011
21
Biology of human sodium glucose transporters.
Ernest M Wright, Donald D F Loo, Bruce A Hirayama. Physiol. Rev. 2011
Ernest M Wright, Donald D F Loo, Bruce A Hirayama. Physiol. Rev. 2011
21
Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
Giovanni Musso, Roberto Gambino, Maurizio Cassader, Elena Paschetta. BMJ 2019
Giovanni Musso, Roberto Gambino, Maurizio Cassader, Elena Paschetta. BMJ 2019
15
Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Thomas Danne, Bertrand Cariou, John B Buse, Satish K Garg, Julio Rosenstock, Phillip Banks, Jake A Kushner, Darren K McGuire, Anne L Peters, Sangeeta Sawhney,[...]. Diabetes Care 2019
Thomas Danne, Bertrand Cariou, John B Buse, Satish K Garg, Julio Rosenstock, Phillip Banks, Jake A Kushner, Darren K McGuire, Anne L Peters, Sangeeta Sawhney,[...]. Diabetes Care 2019
15
Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases.
Susan J Bersoff-Matcha, Christine Chamberlain, Christian Cao, Cindy Kortepeter, William H Chong. Ann. Intern. Med. 2019
Susan J Bersoff-Matcha, Christine Chamberlain, Christian Cao, Cindy Kortepeter, William H Chong. Ann. Intern. Med. 2019
15
Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys.
Motoaki Sano, Makoto Takei, Yasuyuki Shiraishi, Yoshihiko Suzuki. 2016
Motoaki Sano, Makoto Takei, Yasuyuki Shiraishi, Yoshihiko Suzuki. 2016
15
Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1) attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiac SGLT1 causes pathologic hypertrophy and dysfunction in mice.
Mohun Ramratnam, Ravi K Sharma, Stephen D'Auria, So Jung Lee, David Wang, Xue Yin N Huang, Ferhaan Ahmad. J Am Heart Assoc 2014
Mohun Ramratnam, Ravi K Sharma, Stephen D'Auria, So Jung Lee, David Wang, Xue Yin N Huang, Ferhaan Ahmad. J Am Heart Assoc 2014
15
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
15
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
15
SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.
Sanjay K Banerjee, Kenneth R McGaffin, Núria M Pastor-Soler, Ferhaan Ahmad. Cardiovasc. Res. 2009
Sanjay K Banerjee, Kenneth R McGaffin, Núria M Pastor-Soler, Ferhaan Ahmad. Cardiovasc. Res. 2009
15
Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts.
Tsung-Ming Lee, Nen-Chung Chang, Shinn-Zong Lin. Free Radic. Biol. Med. 2017
Tsung-Ming Lee, Nen-Chung Chang, Shinn-Zong Lin. Free Radic. Biol. Med. 2017
15
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Faiez Zannad. JAMA Cardiol 2017
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Faiez Zannad. JAMA Cardiol 2017
15
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
Volker Vallon, Scott C Thomson. Diabetologia 2017
Volker Vallon, Scott C Thomson. Diabetologia 2017
15
Active sugar transport in health and disease.
E M Wright, B A Hirayama, D F Loo. J. Intern. Med. 2007
E M Wright, B A Hirayama, D F Loo. J. Intern. Med. 2007
15
LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.
B Zambrowicz, J Freiman, P M Brown, K S Frazier, A Turnage, J Bronner, D Ruff, M Shadoan, P Banks, F Mseeh,[...]. Clin. Pharmacol. Ther. 2012
B Zambrowicz, J Freiman, P M Brown, K S Frazier, A Turnage, J Bronner, D Ruff, M Shadoan, P Banks, F Mseeh,[...]. Clin. Pharmacol. Ther. 2012
15
Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies.
R J Turner, A Moran. Am. J. Physiol. 1982
R J Turner, A Moran. Am. J. Physiol. 1982
15
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann. Intern. Med. 2013
Despoina Vasilakou, Thomas Karagiannis, Eleni Athanasiadou, Maria Mainou, Aris Liakos, Eleni Bekiari, Maria Sarigianni, David R Matthews, Apostolos Tsapas. Ann. Intern. Med. 2013
15
Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2.
Charles S Hummel, Chuan Lu, Donald D F Loo, Bruce A Hirayama, Andrew A Voss, Ernest M Wright. Am. J. Physiol., Cell Physiol. 2011
Charles S Hummel, Chuan Lu, Donald D F Loo, Bruce A Hirayama, Andrew A Voss, Ernest M Wright. Am. J. Physiol., Cell Physiol. 2011
15
SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.
Yukihiro Chino, Yoshishige Samukawa, Soichi Sakai, Yasuhiro Nakai, Jun-ichi Yamaguchi, Takeo Nakanishi, Ikumi Tamai. Biopharm Drug Dispos 2014
Yukihiro Chino, Yoshishige Samukawa, Soichi Sakai, Yasuhiro Nakai, Jun-ichi Yamaguchi, Takeo Nakanishi, Ikumi Tamai. Biopharm Drug Dispos 2014
15
Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
Linda A Gallo, Ernest M Wright, Volker Vallon. Diab Vasc Dis Res 2015
Linda A Gallo, Ernest M Wright, Volker Vallon. Diab Vasc Dis Res 2015
15
SGLT2 inhibitors act from the extracellular surface of the cell membrane.
Chiara Ghezzi, Bruce A Hirayama, Edurne Gorraitz, Donald D F Loo, Yin Liang, Ernest M Wright. Physiol Rep 2014
Chiara Ghezzi, Bruce A Hirayama, Edurne Gorraitz, Donald D F Loo, Yin Liang, Ernest M Wright. Physiol Rep 2014
15
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Michael E Nassif, Sheryl L Windsor, Fengming Tang, Yevgeniy Khariton, Mansoor Husain, Silvio E Inzucchi, Darren K McGuire, Bertram Pitt, Benjamin M Scirica, Bethany Austin,[...]. Circulation 2019
Michael E Nassif, Sheryl L Windsor, Fengming Tang, Yevgeniy Khariton, Mansoor Husain, Silvio E Inzucchi, Darren K McGuire, Bertram Pitt, Benjamin M Scirica, Bethany Austin,[...]. Circulation 2019
15
Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1).
Lubing Zhou, Ellen V Cryan, Michael R D'Andrea, Stanley Belkowski, Bruce R Conway, Keith T Demarest. J. Cell. Biochem. 2003
Lubing Zhou, Ellen V Cryan, Michael R D'Andrea, Stanley Belkowski, Bruce R Conway, Keith T Demarest. J. Cell. Biochem. 2003
15
Gene deletion of the Na+-glucose cotransporter SGLT1 ameliorates kidney recovery in a murine model of acute kidney injury induced by ischemia-reperfusion.
Josselin Nespoux, Rohit Patel, Kelly L Hudkins, Winnie Huang, Brent Freeman, Young Chul Kim, Hermann Koepsell, Charles E Alpers, Volker Vallon. Am. J. Physiol. Renal Physiol. 2019
Josselin Nespoux, Rohit Patel, Kelly L Hudkins, Winnie Huang, Brent Freeman, Young Chul Kim, Hermann Koepsell, Charles E Alpers, Volker Vallon. Am. J. Physiol. Renal Physiol. 2019
25
Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney.
Volker Vallon, Scott C Thomson. Annu. Rev. Physiol. 2012
Volker Vallon, Scott C Thomson. Annu. Rev. Physiol. 2012
15
The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
Volker Vallon. Annu. Rev. Med. 2015
Volker Vallon. Annu. Rev. Med. 2015
15
The effect of dapagliflozin on renal function in patients with type 2 diabetes.
Donald Elliott Kohan, Paola Fioretto, Kristina Johnsson, Shamik Parikh, Agata Ptaszynska, Lisa Ying. J. Nephrol. 2016
Donald Elliott Kohan, Paola Fioretto, Kristina Johnsson, Shamik Parikh, Agata Ptaszynska, Lisa Ying. J. Nephrol. 2016
15
Renal effects of canagliflozin in type 2 diabetes mellitus.
Vlado Perkovic, Meg Jardine, Ujjwala Vijapurkar, Gary Meininger. Curr Med Res Opin 2015
Vlado Perkovic, Meg Jardine, Ujjwala Vijapurkar, Gary Meininger. Curr Med Res Opin 2015
15
Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus.
H Sims, K H Smith, P Bramlage, J Minguet. Diabet. Med. 2018
H Sims, K H Smith, P Bramlage, J Minguet. Diabet. Med. 2018
30
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members.
Jian Chen, Sandy Williams, Samantha Ho, Howard Loraine, Deborah Hagan, Jean M Whaley, John N Feder. 2010
Jian Chen, Sandy Williams, Samantha Ho, Howard Loraine, Deborah Hagan, Jean M Whaley, John N Feder. 2010
15
Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.
Hongyu Qiu, Aleksandra Novikov, Volker Vallon. Diabetes Metab. Res. Rev. 2017
Hongyu Qiu, Aleksandra Novikov, Volker Vallon. Diabetes Metab. Res. Rev. 2017
15
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.